Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Phase 2 × Plasmablastic Lymphoma × daratumumab × Clear all

Phase

Phase EARLY_PHASE1 1 Phase 2 1

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Multiple Myeloma 95 Recurrence 11 Neoplasms, Plasma Cell 9 Immunoglobulin Light-chain Amyloidosis 6 Neoplasms 5 Smoldering Multiple Myeloma 3 Precursor T-Cell Lymphoblastic Leukemia-Lymphoma 3 Waldenstrom Macroglobulinemia 2 Precursor Cell Lymphoblastic Leukemia-Lymphoma 2 Plasmacytoma 2 Neoplasm, Residual 2 Lymphoma 2 Leukemia, Myeloid, Acute 2 Leukemia, Lymphocytic, Chronic, B-Cell 2 Renal Insufficiency 1 Prostatic Neoplasms 1 Plasmablastic Lymphoma 1 Paraproteinemias 1 Non-small Cell Lung Cancer With STK11/LKB1 Mutation 1 Myelodysplastic Syndromes 1 Microsatellite Unstable Colorectal Cancer 1 Malignant Neoplasms Stated as Primary Lymphoid Haematopoietic 1 Lymphoma, T-Cell 1 Lymphoma, Mantle-Cell 1 Lymphoma, Large B-Cell, Diffuse 1 Lymphoma, Follicular 1 Leukemia, Plasma Cell 1 Hypergammaglobulinemia 1 Disease 1 Chromosome 17 deletion 1

Interventions

varlilumab 1 daratumumab 1 belantamab mafodotin 1 Vincristine 1 Rituximab 1 Prednisone 1 Nivolumab 1 Immunoglobulin G 1 Etoposide 1 Doxorubicin 1 Disulfides 1 Dexamethasone 1 Cyclophosphamide 1 Bortezomib 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT04915248 2025-12-24

FIL_DALYA

Fondazione Italiana Linfomi - ETS

Phase 2 Recruiting

Plasmablastic Lymphoma, Lymphoma, Recurrence

Data powered by HemOnc (CC BY 4.0) Colophon ⚡